New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - heparin sodium 10 iu/ml - solution for injection - 50 iu/5ml - active: heparin sodium 10 iu/ml excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - gemtuzumab ozogamicin 5mg - powder for injection - 5 mg - active: gemtuzumab ozogamicin 5mg excipient: dextran 40 dibasic sodium phosphate monobasic sodium phosphate monohydrate sodium chloride sucrose - mylotarg is indicated for combination therapy with standard anthracycline and cytarabine (arac) for the treatment of patients age 15 years and above with previously untreated, de novo cd33-positive acute myeloid leukaemia (aml), except acute promyelocytic leukaemia (apl).

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - neisseria meningitidis group b factor h binding protein subfamily a 0.12 mg/ml;  ; neisseria meningitidis group b factor h binding protein subfamily b 0.12 mg/ml;   - suspension for injection - 120 mcg/0.5ml - active: neisseria meningitidis group b factor h binding protein subfamily a 0.12 mg/ml   neisseria meningitidis group b factor h binding protein subfamily b 0.12 mg/ml   excipient: aluminium as aluminium phosphate histidine polysorbate 80 sodium chloride water for injection - trumenba is indicated in individuals 10 years and older for active immunisation to prevent invasive meningococcal disease caused by neisseria meningitidis serogroup b.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - crizotinib 200mg;  ;   - capsule - 200 mg - active: crizotinib 200mg     excipient: calcium hydrogen phosphate colloidal silicon dioxide gelatin iron oxide red magnesium stearate microcrystalline cellulose sodium starch glycolate tekprint black sw-9008 titanium dioxide - xalkori is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). xalkori is indicated for the treatment of patients with ros1-positive advanced non-small cell lung cancer (nsclc).

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - crizotinib 250mg;  ;   - capsule - 250 mg - active: crizotinib 250mg     excipient: calcium hydrogen phosphate colloidal silicon dioxide gelatin iron oxide red magnesium stearate microcrystalline cellulose sodium starch glycolate tekprint black sw-9008 titanium dioxide - xalkori is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). xalkori is indicated for the treatment of patients with ros1-positive advanced non-small cell lung cancer (nsclc).

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - reboxetine mesilate 2.612mg equivalent to 2 mg reboxetine free base - tablet - 2 mg - active: reboxetine mesilate 2.612mg equivalent to 2 mg reboxetine free base excipient: calcium hydrogen phosphate dihydrate crospovidone hydrated silica magnesium stearate powdered cellulose - reboxetine is indicated for the treatment of depressive illness and for maintaining the clinical improvement in patients initially responding to treatment. the remission of the acute phase of the depressive illness is associated with an improvement in the patient's quality of life in terms of social adaptation.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 16.7mg equivalent to 12.5 mg sunitinib;   - capsule - 12.5 mg - active: sunitinib malate 16.7mg equivalent to 12.5 mg sunitinib   excipient: croscarmellose sodium gelatin iron oxide red magnesium stearate mannitol povidone propylene glycol shellac sodium hydroxide sodium laurilsulfate titanium dioxide - sutent is indicated for the treatment of advanced renal cell carcinoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 33.4mg equivalent to 25 mg sunitinib;   - capsule - 25 mg - active: sunitinib malate 33.4mg equivalent to 25 mg sunitinib   excipient: croscarmellose sodium gelatin iron oxide black iron oxide red iron oxide yellow magnesium stearate mannitol povidone propylene glycol shellac sodium hydroxide sodium laurilsulfate titanium dioxide - sutent is indicated for the treatment of advanced renal cell carcinoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 66.8mg equivalent to 50 mg sunitinib;   - capsule - 50 mg - active: sunitinib malate 66.8mg equivalent to 50 mg sunitinib   excipient: croscarmellose sodium gelatin iron oxide black iron oxide red iron oxide yellow magnesium stearate mannitol povidone propylene glycol shellac sodium hydroxide sodium laurilsulfate titanium dioxide - sutent is indicated for the treatment of advanced renal cell carcinoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 50.1mg equivalent to 37.5mg sunitinib;   - capsule - 37.5 mg - active: sunitinib malate 50.1mg equivalent to 37.5mg sunitinib   excipient: croscarmellose sodium gelatin ink iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - sutent is indicated for the treatment of advanced renal cell carcinoma.